Clinical application and progress of 68Ga-FAPI PET in the diagnosis and treatment of ovarian cancer
10.3760/cma.j.cn321828-20240510-00162
- VernacularTitle:68Ga－FAPI PET在卵巢癌诊疗中的临床应用进展
- Author:
Qianpeng YE
1
;
Guangming LI
1
Author Information
1. 广州医科大学附属清远医院（清远市人民医院）影像中心，清远 511518
- Publication Type:Journal Article
- Keywords:
Ovarian neoplasm;
Antagonists and inhibitors;
Membrane proteins;
Fibroblasts;
Gallium radioisotopes;
Positron-emission tomography;
Trends
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2025;45(5):313-316
- CountryChina
- Language:Chinese
-
Abstract:
The pathogenesis of ovarian cancer is concealed, which is prone to recurrence and metastasis and carries a very poor prognosis. The precise imaging assessment of abdominopelvic tumor burden is crucial for debulking surgery decision in patients with ovarian cancer. Fibroblast activation protein inhibitor (FAPI) PET imaging has shown a great prospect of clinical application, which provides a new imaging technique for the diagnosis and staging of ovarian cancer. This review summarizes the clinical value and research progress of 68Ga-FAPI PET in the diagnosis and treatment of ovarian cancer.
